See more : Frøy ASA (FROY.OL) Income Statement Analysis – Financial Results
Complete financial analysis of EastWest Bioscience Inc. (HBOSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EastWest Bioscience Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Green World Hotels Co., Ltd. (8077.TWO) Income Statement Analysis – Financial Results
- Evadix Sa (ALEVA.BR) Income Statement Analysis – Financial Results
- Toho Chemical Industry Company, Limited (4409.T) Income Statement Analysis – Financial Results
- MEGMILK SNOW BRAND Co.,Ltd. (2270.T) Income Statement Analysis – Financial Results
- Premium Water Holdings,Inc. (2588.T) Income Statement Analysis – Financial Results
EastWest Bioscience Inc. (HBOSF)
About EastWest Bioscience Inc.
EastWest Bioscience Inc., a vertically-integrated wellness company, manufactures and sells hemp nutritional products in Canada and the United States. The company also operates Sangster's Health Center stores that sells supplements and wellness products through its franchise locations and online ecommerce platform. In addition, it is involved in the property management business. EastWest Bioscience Inc. was founded in 2016 and is headquartered in Penticton, Canada.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 627.27K | 922.56K | 1.40M |
| Cost of Revenue | 598.96K | 821.22K | 1.04M |
| Gross Profit | 28.31K | 101.34K | 355.61K |
| Gross Profit Ratio | 4.51% | 10.98% | 25.46% |
| Research & Development | 11.44K | 2.66K | 7.29K |
| General & Administrative | 2.38M | 2.45M | 4.46M |
| Selling & Marketing | 99.61K | 67.43K | 145.01K |
| SG&A | 2.22M | 1.89M | 3.56M |
| Other Expenses | -24.43K | -14.42K | -61.45K |
| Operating Expenses | 2.25M | 1.91M | 3.63M |
| Cost & Expenses | 2.85M | 2.73M | 4.67M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 257.29K | 223.37K | 259.28K |
| Depreciation & Amortization | 118.62K | 126.67K | 136.22K |
| EBITDA | -1.65M | -1.73M | -3.13M |
| EBITDA Ratio | -335.11% | -182.47% | -224.36% |
| Operating Income | -2.22M | -1.81M | -3.27M |
| Operating Income Ratio | -354.03% | -196.20% | -234.11% |
| Total Other Income/Expenses | 7.97K | 155.33K | -705.04K |
| Income Before Tax | -1.64M | -1.11M | -3.66M |
| Income Before Tax Ratio | -261.49% | -120.18% | -261.80% |
| Income Tax Expense | -32.98K | 23.06K | 9.64K |
| Net Income | -1.61M | -1.13M | -3.67M |
| Net Income Ratio | -256.23% | -122.68% | -262.49% |
| EPS | -0.02 | -0.01 | -0.05 |
| EPS Diluted | -0.02 | -0.01 | -0.05 |
| Weighted Avg Shares Out | 94.73M | 83.77M | 79.09M |
| Weighted Avg Shares Out (Dil) | 94.73M | 83.77M | 79.09M |
EastWest Bioscience Announces Shares for Debt Settlement
EastWest Bioscience Announces Grant of Options and Debt Settlement
Eastwest Announces Resignation of CFO and Appointment of Interim CFO
Source: https://incomestatements.info
Category: Stock Reports